Endologix

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Endologix and buy or sell other stocks, ETFs, and their options commission-free!

About ELGX

Endologix LLC engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix, and Ovation. 

CEO
John Randall Liddicoat, MD, MBA
CEOJohn Randall Liddicoat, MD, MBA
Employees
Employees
Headquarters
Irvine, California
HeadquartersIrvine, California
Founded
1992
Founded1992
Employees
Employees

ELGX Key Statistics

Market cap
411.10K
Market cap411.10K
Price-Earnings ratio
-0.01
Price-Earnings ratio-0.01
Dividend yield
Dividend yield
Average volume
302.24K
Average volume302.24K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$3.96
52 Week high$3.96
52 Week low
$0.01
52 Week low$0.01

Stock Snapshot

As of today, Endologix(ELGX) shares are valued at $0.22. The company's market cap stands at 411.1K, with a P/E ratio of -0.01.

On 2026-03-10, Endologix(ELGX) stock opened at —, reached a high of —, and a low of —.

The Endologix(ELGX)'s current trading volume is 0, compared to an average daily volume of 302.24K.

During the past year, Endologix(ELGX) stock moved between $0.01 at its lowest and $3.96 at its peak.

During the past year, Endologix(ELGX) stock moved between $0.01 at its lowest and $3.96 at its peak.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.